DS 1103a
Alternative Names: DS-1103; DS-1103aLatest Information Update: 06 Jul 2023
At a glance
- Originator Daiichi Sankyo Company
- Developer AstraZeneca; Daiichi Sankyo Company
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action SIRPA protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 02 Jun 2023 Pharmacodynamics data from a preclinical trial in solid tumours presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 30 May 2023 Phase-I clinical trials in Solid tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (IV) (NCT05765851)
- 13 Mar 2023 Daiichi Sankyo in collaboration with AstraZeneca plans a phase I trial for Solid Tumours (Late-stage disease, Combination therapy, Metastatic disease, Inoperable/unresectable) in the US (IV, Infusion) in April 2023 (NCT05765851)